目的观察纤溶酶治疗急性脑梗死(ACI)的临床疗效和副作用。方法102例ACI患者被随机分成两组:治疗组52例,对照组50例,两组患者均为发病72小时内的急性期病例。两组基础治疗相同。治疗组用纤溶酶注射液静脉滴注,连用10天。对照组用灯盏细辛注射液静脉滴注。采用1995年全国第4届脑血管病学术会议制定的《脑卒中患者临床神经功能缺损程度评分标准》(CSS)观察治疗前及治疗后5、11天的临床疗效,比较治疗前及治疗后11天时两组脑梗死体积大小及血液流变学检查结果以及治疗的副作用。结果:CSS评定治疗组总有效率达92.3%,对照组总有效率达72.0%,两组对比疗效差异有显著性(P<0.05)。用药后5天与用药前,用药后11天与用药后5天比较均有显著性差异(P<0.05)。11天时两组脑梗死体积比较有显著性差异(P<0.05)。11天时两组血液流变学检查结果有显著性差异(P<0.05)。两组均未发现明显副作用。结论纤溶酶治疗急性脑梗死的疗效比常规治疗好,无明显不良反应。 Objective To observe the clinical efficacy and side effects of plasmin in the treatment of acute cerebral infarction (ACI). Methods A total of 102 patients with ACI were randomly divided into two groups: treatment group (52 cases) and control group (50 cases). Both groups were acute cases within 72 hours after onset. The same two groups of basic treatment. Treatment group with intravenous infusion of fibrinolytic injection, once every 10 days. Control group with Erigeron Injection intravenous drip. The clinical efficacy of pre-treatment and post-treatment 5 and 11 days was evaluated using the “Clinical Neurological Deficiency Criteria Scale for Stroke Scale” (CSS) developed at the Fourth National Conference on Cerebrovascular Diseases in 1995. The results were compared before treatment and after treatment Day two groups of cerebral infarction size and blood rheology examination results and treatment side effects. Results: The total effective rate of the treatment group was 92.3% and the total effective rate of the control group was 72.0%. There was significant difference between the two groups (P <0.05). There was a significant difference (P <0.05) between the 5 days after treatment and before treatment, 11 days after treatment and 5 days after treatment. There was a significant difference in the volume of cerebral infarction between the two groups on day 11 (P <0.05). On the 11th day, there was a significant difference between the two groups in the results of hemorheology (P <0.05). No obvious side effects were found in both groups. Conclusion The efficacy of plasmin in the treatment of acute cerebral infarction is better than that of routine treatment and no obvious adverse reactions.